SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
The purpose of this study placebo-controlled, randomized, double-blind study is to assess the
 safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD) already
 treated with a stable dose of a cholinesterase inhibitor.
This study includes a Screening Period of up to 6 weeks, a 16 week Treatment Period, and a 2
 week Safety Follow Up Period.

 Final eligibility will be determined at the Baseline Visit. Eligible patients will be
 randomized to receive placebo or SYN120 100 mg once a day (QD).
Inclusion Criteria:

 -  Parkinson's Disease Dementia

 -  Patient has a routine caregiver

 -  Taking a stable cholinesterase inhibitor.

 -  Patient has a Montreal Cognitive Assessment (MoCA) 10-23 inclusive

 Exclusion Criteria:

 -  History of any significant neurologic or psychiatric disease other than PD

 -  Any other condition or clinically significant abnormal findings that would make the
 patient unsuitable for the study

 -  Unpredictable motor fluctuations that would interfere with administering assessments